Literature DB >> 15349009

Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment.

Daniel Kopf1, Sabine Westphal, Claus W Luley, Susanne Ritter, Maria Gilles, Bettina Weber-Hamann, Florian Lederbogen, Hendrik Lehnert, Fritz A Henn, Isabella Heuser, Michael Deuschle.   

Abstract

Major depression increases cardiovascular risk despite lower cholesterol levels. Little is known about effects of antidepressants on metabolic risk factors. We studied lipoprotein composition, insulin sensitivity (quantitative insulin sensitivity check index), and saliva cortisol in 78 depressed patients before and after 35 days of amitriptyline or paroxetin treatment. Data were analyzed by principal component factor analyses and analysis of variance (ANOVA). At baseline, quantitative insulin sensitivity check index was inversely correlated with cortisol (r = -0.46; P = 0.005) in normal weight patients, with body mass index in overweight patients (r = -0.50; P < 0.001). In overweight patients, hypercortisolemia correlated inversely with total and low density lipoprotein cholesterol (eg, cortisol at 4:00 PM and low density lipoprotein cholesterol: r = -0.49, P = 0.002). After treatment, quantitative insulin sensitivity check index was unchanged. Triglycerides increased in responders to amitriptyline only (P < 0.05). Parameters of cholesterol metabolism improved slightly without differences between treatment groups (eg, high density lipoprotein: pre 43.5 +/- 12.0; post 47.6 +/- 13.0 mg/dL; P = 0.01; low density lipoprotein triglycerides, a measure of low density lipoprotein atherogenicity: pre 458 +/- 120; post 415 +/- 130 mg/g; P < 0,01). The inverse correlation of cortisol and cholesterol, at least in the obese subgroup, proposes a mechanism for the known association of depression with low cholesterol. As determinants of plasma lipids in major depression, we identified body mass index, insulin sensitivity, and cortisol. Although uncontrolled, our data suggest that treatment of depression exerts a mainly beneficial effect on lipid regulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15349009     DOI: 10.1097/01.jcp.0000138762.23482.63

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  18 in total

Review 1.  The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Authors:  Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

2.  The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients.

Authors:  Georgios Paslakis; Maria Gilles; Florian Lederbogen; Claudia Schilling; Barbara Scharnholz; Michael Deuschle
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-10-30       Impact factor: 5.270

3.  Hypercortisolemic depression is associated with the metabolic syndrome in late-life.

Authors:  Nicole Vogelzangs; Kristen Suthers; Luigi Ferrucci; Eleanor M Simonsick; Alessandro Ble; Matthew Schrager; Stefania Bandinelli; Fulvio Lauretani; Sandra V Giannelli; Brenda W Penninx
Journal:  Psychoneuroendocrinology       Date:  2007-01-16       Impact factor: 4.905

Review 4.  Stress and its role in sympathetic nervous system activation in hypertension and the metabolic syndrome.

Authors:  Elisabeth A Lambert; Gavin W Lambert
Journal:  Curr Hypertens Rep       Date:  2011-06       Impact factor: 5.369

5.  Mental health symptoms and patient-reported diabetes symptom burden: implications for medication regimen changes.

Authors:  Dara H Sorkin; John Billimek; Kristin J August; Quyen Ngo-Metzger; Sherrie H Kaplan; Andrew R Reikes; Sheldon Greenfield
Journal:  Fam Pract       Date:  2015-04-05       Impact factor: 2.267

6.  Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients.

Authors:  Gualberto Ruaño; David Villagra; Bonnie Szarek; Andreas Windemuth; Mohan Kocherla; Krystyna Gorowski; Christopher Berrezueta; Harold I Schwartz; John Goethe
Journal:  Biomark Med       Date:  2011-08       Impact factor: 2.851

Review 7.  [Psychotropic drugs and diabetes].

Authors:  Claudia Ress; Alexander Tschoner; Susanne Kaser; Christoph F Ebenbichler
Journal:  Wien Med Wochenschr       Date:  2011-07-29

Review 8.  Harmful effects of functional hypercortisolism: a working hypothesis.

Authors:  Giacomo Tirabassi; Marco Boscaro; Giorgio Arnaldi
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

9.  Cholesterol and affective morbidity.

Authors:  Jess G Fiedorowicz; Narasimha M Palagummi; Ole Behrendtsen; William H Coryell
Journal:  Psychiatry Res       Date:  2009-12-06       Impact factor: 3.222

10.  Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males.

Authors:  Yi-Chyan Chen; Wei-Win Lin; Yu-Jung Chen; Wei-Chung Mao; Yi-Jen Hung
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.